Thirty years ago, a young healthcare attorney sat across from small hospital pharmacy teams and told them to get ready. 340B, the federal drug discount program many of them relied on to stay open, was going away. Everyone said so.
Three decades later, that attorney is Kim Tzoumakas, now CEO of VytlOne, and she still hears the same prediction every year. She has stopped believing it.
Kim spent her first twenty years embedded inside hospitals and health systems as a healthcare lawyer, then ran two large provider businesses before pharmacy: she was CEO of RAYUS Radiology and CEO of 21st Century Oncology. Now she runs VytlOne, the roughly 100-year-old pharmacy services company she rebranded and merged into its current form after taking the job, a business that generated $1.4 billion for its pharmacy partners in a single year. Its newest bet is VytlAIQ, an end-to-end intelligence platform built from the ground up rather than grafted onto a legacy system. Read More >
